Breaking News

Takeda Divests Assets to Hypera for $825M

Portfolio includes OTC and prescription pharmaceutical products from Takeda's Growth & Emerging Markets BU

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. Ltd. has entered an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A., Brazil’s largest pharmaceutical company, for $825 million. The portfolio includes OTC and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth & Emerging Markets Business Unit. Takeda anticipates that approximately 300 commercial employee...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters